DGAP-News: BP p.l.c.: Transaction in Own Shares

BP p.l.c.

 

Transaction in Own Shares

 

BP p.l.c. (the "Company") announces that on 25 April 2022 it has purchased, in accordance with the authority granted by shareholders at the 2021 Annual General Meeting of the Company, a total of 6,000,000 of its ordinary shares of $0.25 each ("Shares") on the London Stock Exchange and Cboe (UK) as part of the buyback programme announced on 8 February 2022 (the "Programme") and as detailed below:

 

	London Stock Exchange	Cboe (UK)/BXE	Cboe (UK)/CXE
Number of Shares purchased:	3,000,000	2,000,000	1,000,000
Highest price paid per Share (pence):	382.9500	382.8500	382.9000
Lowest price paid per Share (pence):	370.5000	370.5000	370.4500
Volume weighted average price paid per Share (pence):	374.8439	375.0976	375.1058

 

The Company intends to cancel these shares in accordance with the intentions expressed in connection with the authority granted by its shareholders at the Company's 2021 Annual General Meeting.

 

The schedule below contains detailed information about the purchases made by Citigroup Global Markets Limited (intermediary code: SBILGB2L) on the date of purchase as part of the Programme.

 

Further enquiries:

bp Investor Relations         +44(0) 207 496 4000

 

Schedule of Purchases

 

Shares purchased: BP p.l.c. (ISIN CODE: GB0007980591)

 

Aggregate information:

 

Venue	Volume-weighted average price (pence)	Aggregated volume
London Stock Exchange	374.8439	3,000,000
Cboe (UK)/BXE	375.0976	2,000,000
Cboe (UK)/CXE	375.1058	1,000,000

 

Individual transactions:

 

To view details of the individual transactions, please paste the following URL into the address bar of your browser.

 

http://www.rns-pdf.londonstockexchange.com/rns/2719J_1-2022-4-25.pdf

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.